AVEO Oncology and Astellas Pharma Inc. discontinued a phase II study of tivozanib in locally recurrent or metastatic triple-negative breast cancer due to insufficient enrollment.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe